Intensive chemotherapy and bone marrow transplantation for children with acute myeloid leukemia.

secondary AML, and granulocytic sarcoma, in contrast in AML-BFM 93 only patients younger than 18 years) showed that the overall 5-year survival rate of all children, not only those in remission, was 59% Ϯ 2%. This was considerably higher than of the total patient group of the CCG 2891 trial (CCG estimated 40%; intensive timing 49% Ϯ 5%; standard timing 34% Ϯ 6%). Events 5 years after diagnosis were extremely rare in the BFM studies, and therefore, estimates are comparable. It is surprising that the survival curve from the BMT group in the CCG study shows no plateau after more than 5 years. 1(Fig2) This is in contrast to the chemotherapy groups in the CCG and in the BFM study.